Guadecitabine- Astex Pharmaceuticals

Drug Profile

Guadecitabine- Astex Pharmaceuticals

Alternative Names: Decitabine deoxyguanosine; Decitabine deoxyguanosine dinucleotide; S-110; SGI-110

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SuperGen
  • Developer Astex Pharmaceuticals; Columbia University; Genentech; John Hopkins University; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); Weill Cornell Medical College
  • Class Antineoplastics; Aza compounds; Deoxyribonucleosides; Furans; Purine nucleosides; Small molecules; Triazines
  • Mechanism of Action Antimetabolites; DNA cytosine 5 methyltransferase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Phase II Gastrointestinal stromal tumours; Hepatocellular carcinoma; Myeloproliferative disorders; Ovarian cancer; Pheochromocytoma; Renal cell carcinoma; Solid tumours
  • Phase I/II Bladder cancer; Colorectal cancer
  • Phase I Malignant melanoma; Non-small cell lung cancer; Small cell lung cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Second-line therapy or greater) in Japan (SC, Injection)
  • 14 Oct 2017 AstraZeneca and Big Ten Cancer Research Consortium plans a phase Ib/II trial for Renal cancer, Clear cell renal cell carcinoma (Combination therapy, Metastatic disease, Late-stage disease, Second-line therapy or greater) in USA in October 2017 (NCT03308396)
  • 29 Aug 2017 University of Southern California in collaboration with National Cancer Institute plans a phase Ib trial of guadecitabine and durvalumab for Hepatocellular carcinoma, Pancreatic adenocarcinoma, and Cholangiocarcinoma/Gallbladder cancer (Late-stage disease, Combination therapy) in USA in September 2017 (NCT03257761)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top